Adults suffering from rheumatoid arthritis who have not fully responded to treatment many soon have a new treatment option available to them. The FDA has approved a subcutaneous formulation of tocilizumab (Actemra), which has shown a 20% improvement based on the American College of Rheumatology criteria in 70% of patients.
Chief medical officer of the drug’s manufacturer has stated in a press release that the treatment can potentially prevent irreversible joint damage in patients with moderate to severely active rheumatoid arthritis.
Read more: FDA Greenlights Sub Q Actemra
Powered by Facebook Comments